Eric Walczykowski

🔍 Curious about the value of attending private equity conferences? Our new article breaks down 25 compelling reasons why executives should invest in their professional growth by attending these events. From networking with key industry players to acquiring strategic insights, the ROI is substantial. Read more here: https://buff.ly/3LZnxOV 💼 Learn more about Blackmore Partners: https://buff.ly/42iNmB3 📅 Have questions? Schedule a meeting with our Director Chris Melton here: https://buff.ly/46DZD46 #PrivateEquity #CareerGrowth #ExecutiveRoles #BlackmorePartners #PECareers

7

Such an excellent conversation this week. For those in venture capital, this is a must listen. https://lnkd.in/gQUgM8q9

1

1 Comment

Here is an article I put together that helps explain indemnification. Indemnification is one of the most misunderstood and negotiated topics in corporate and commercial agreements. This article helps demystify indemnification (in the context of technology transactions) for business professionals.

24

3 Comments

Our partner Eddie Eltoukhy has identified these opportunities in Biotech. Eddie has a PhD in bioengineering from Massachusetts Institute of Technology and over a decade experience as an operator. Reach out to him if you are working on these areas of biotech. Pear VC - Technology-Driven Therapeutic Platforms Companies developing therapeutic assets with a core product engine Proprietary tool, workflow, or samples leading to novel biological data sets Preference for omics platforms or high throughput screening / engineering workflows First-in-class or best-in-class drugs - Next-Generation Therapeutic Modalities Technologies to improve the efficacy, safety, access, or reach of next-gen modalities including the following: Genomic medicines (gene tx & gene editing) Cell therapies Targeted protein degraders Antibody-drug conjugates Radiopharma - Precision Medicine New technologies supporting the discovery of novel biomarkers and the generation of proprietary data sets for applications in: Disease screening Therapy selection Recurrence monitoring - Life Sciences + AI Software Platforms Software & AI-driven platforms to improve all aspects of life sciences R&D, including: Target discovery and validation Drug design and optimization Manufacturing Regulatory Clinical development

118

5 Comments

If you believe that #Diversity and #Inclusion matter, specifically in times like this, join us on October 30th. We will discuss the challenges and success stories of promoting Diversity in 2024. With me you will find industry leaders who were able to pull it off (!) 💥💥💥 Dorit Dor, Hasan Abasi, Vered Raviv Schwarz, Gal Shaul Guesty, Augury, HAAT Delivery, Check Point Software Power in Diversity Glilot Capital Partners Poalim Tech, Meitar | Law Offices, ESOP - Phoenix, Microsoft, Calcalist כלכליסט #nomatterwhat

34

1 Comment

I’m a strong believer in the idea that leading is largely about building empathy. The job isn’t just helping others understand the mission - it’s helping them complete the mission and building alignment through personal context. To take it a step further, you can’t be empathetic if you aren’t curious. Curiosity drives us to ask deeper questions - those questions build empathy and, then, we become more aligned.

6